PHP1 Incorporating the Patient's Voice Into the Assessment of Medical Devices: A Comparison of the United States and Europe  by Doward, L. et al.
were clearly judged favourable or unfavourable. In decisions where the evidence
was rated uncertain or was not assessed, we found that the number of stakeholders
participating in the voting stage (odds ratio2.52; p0.03) and the scientific rigour
in assessment of costs/cost-effectiveness (OR6.25; p0.06) increased the likeli-
hood of a positive decision outcome. On the contrary, it significantly decreased for
prescribed medicines (OR0.05; p0.003). CONCLUSIONS: Despite claims for mak-
ing transparent and participative coverage decisions, the phase of evidence gener-
ation and synthesis is most critical for technology appraisal. Decison makers usu-
ally adapt the assessment recommendations. Decision outcomes seem to a large
extent independent of how processes are configured.
PODIUM SESSION III:
VACCINE RESEARCH
VA1
A EUROPEAN-WIDE STUDY ON THE ROLE OF STREPTOCOCCUS PNEUMONIAE
IN COMMUNITY-ACQUIRED PNEUMONIA AMONG ADULTS: A META-ANALYSIS
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OBJECTIVES: Community-acquired pneumococcal pneumonia is an important
cause of hospitalization and death among adults, but figures on the prevalence of
Streptococcus pneumoniae largely vary. We aimed to identify the prevalence of Strep-
tococcus pneumoniae by systematically reviewing all available etiological studies of
adult patients with community-acquired pneumonia (CAP) over the period January
1990- November 2011 across European countries. METHODS: Two reviewers con-
ducted a systematic literature search using PubMed of English-language articles on
the prevalence of adult CAP caused by S. Pneumoniae and manually reviewed the
article bibliographies. A mixed-effects meta-regression model was developed and
populated with 24,236 patients obtained from 79 articles that met in- and exclusion
criteria. The meta-regression was adjusted for country and region characteristics
as well as other possible independent covariates. RESULTS: The findings from the
mixed-effects meta-regression model indicate that the observed prevalence of S.
pneumoniae in CAP significantly differs between European regions even after ad-
justing for various covariates including patient characteristics, diagnostic tests,
antibiotic resistance and health-care setting. Performing a diagnostic PCR assay
increased the probability of detecting S. pneumoniae substantially, compared to all
other diagnostic tests included. Furthermore, S. pneumoniae was more likely to be
confirmed as the cause of a CAP in cases treated in the ICU as compared to those
treated in the hospital or in the community. CONCLUSIONS: This study provides
estimates of the prevalence of S. Pneumoniae in CAP, independent of study design,
or other risk factors, which could be used for predictions of the health and eco-
nomic impact of adult pneumococcal vaccination.
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OBJECTIVE: A fundamental information needed to conduct economic evaluations
of vaccines is effectiveness against disease. However, effectiveness is not always
observed directly and relies on an immunological response that predicts protec-
tion. Typical immune responses which are predictive of protection are neutralizing
antibodies, called surrogates or correlates of protection (COP). Often the COP is
reduced to a threshold value that differentiates between protected and susceptible.
COPs are relied on in place of estimates of effectiveness and for immunization
policy, however there are no consistent criteria or statistical methods for establish-
ing candidate immune response as predictive COP. Our aims were to review pro-
posed hierarchies of evidence necessary to establish a COP and statistical methods
used to relate immune responses to protection. METHODS: The strength of evi-
dence for demonstrating a COP based on different frameworks and early and mod-
ern statistical methods approaches to establish a COP were reviewed. Findings and
Recommendations: Different frameworks define different levels of confidence in
COPs. The Prentice framework is significance testing-driven and requires protec-
tion to be related to vaccination, the correlate related to the vaccine and correlate
related to clinical endpoint. Moreover vaccination should not add additional infor-
mation on protection over that explained by the correlate. A framework by Qin
proposes levels of evidence based on single or multiple randomized trials. To esti-
mate thresholds, early vaccine studies relied on inspection of disease rates ob-
served in discrete intervals of assay values. Modern examples employed Chang-
Kohberger method, but this requires an estimate of vaccine efficacy based on
occurrence of disease before it can be used. The scaled-logit model permits esti-
mation of continuous protection curves by antibody titer. In addition to statistical
criteria, other considerations include clear endpoint definition, laboratory assays,
host and population factors. New statistical methods should be developed and
tested within evidence frameworks to better obtain estimates of vaccine effective-
ness.
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OBJECTIVES: Influenza is a disease that occurs every year for a few months in
winter season. Predictions on vaccination strategies require a deep understanding
of current influenza epidemics. The aim of this work is the reproduction of a past
influenza season through a model, its examination and to make its dynamics
transparent. METHODS: We used an agent based epidemic model to simulate the
spread of influenza. It belongs to the class of dynamic transmission models and
simulates single persons with individual behavior who live in an environment,
meet each other and spread the virus from person to person upon contacts. Con-
tacts are based on statistical data and social studies; epidemiological parameters
are found in clinical studies and through calibration. RESULTS: Estimates say that
about 5% of the population fall sick with influenza every year in Austria. The model
shows clearly that this number is highly implausible under naive assumptions
because the epidemic would not behave like this; instead it would be much stron-
ger or die out – depending on the parameters. This reveals that our knowledge on
influenza is insufficient. Three additional assumptions might solve the problem:
First, that the influenza season highly depends on the seasonal climate, second,
that many people are generally resistant for the whole season and third, that many
people undergo infections without symptoms. Simulation of these assumptions
reveal three different possible propagations of the influenza that all result in 5%
sick people. CONCLUSIONS: The model cannot answer all questions about influ-
enza. But it is able to show clearly where we need more information and it provides
the possibility to test different assumptions and evaluate them. In other words, the
model can lead to a deeper understanding of the real world by examining assump-
tions that could not be observed directly so far.
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OBJECTVES: Pre-launch economic models are constructed to simulate long-term
changes in costs and effects. Typically Markov cohort models are used, whereas the
input often available to parameterize the models is obtained from cross-sectional,
annual, population data. The question is how to make the link and reconcile results
from long-term cohort models with annual observed population data? An illustra-
tion is given with modelled and observed hospitalisations due to rotavirus related
acute gastroenteritis. METHODS: The spread of hospitalisations of children up to
the age of 5 years, observed over a one -year period follows a normal distribution
(seasonality of the infection) with a peak around February March each year. The
assessment is done by 1-year age-groups (0 to 1y; 1 to 2y; 2 to 3y; 3 to 4y; 4 to 5y). The
parameters of this normal distribution are used to construct an overall modelled
population density curve with the same annual spread. Within this construction
the weekly spread of hospitalisations by age follows the density curve of the cohort
model with an age-specific Weibull distribution. To compare the model results
with the observation we analyse the age-group spread of hospitalisations but also
the results following the introduction of a specific intervention such as
vaccination. RESULTS: Pre-vaccination, the fit of the age-related spread of hospi-
talisations modelled using the population model to the observed data was compel-
ling (regression-scale model fit  0.05). Post-vaccination the modelled and ob-
served reduction in hospitalisations matched, however in the unvaccinated older
children the model predicted a lower reduction than observed which could be
explained by a herd protection effect in the observed population (indirect vaccine
benefit). Herd protection was not captured in the static model. CONCLUSIONS: It is
possible to make the link between cohort models and observed population data
provided the underlying model characteristics reflect reality.
RESEARCH POSTER PRESENTATIONS – SESSION I
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HEALTH CARE USE & POLICY STUDIES - Consumer Role In Health Care
PHP1
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OBJECTIVES: Medical devices (MDs) play a major role in many aspects of health
care. The United States (US) and Europe (EU) categorise MDs into different classes,
with greatest regulatory control imposed on the highest risk Class III devices. In the
US, the Food and Drug Administration (FDA) approves Class-III MDs. In EU, the
European Commission sets the regulatory framework through which ‘notified bod-
ies’ confer a Confomité Européene (CE) mark for MDs. The purpose of this study
was to evaluate the extent to which patient-reported outcomes (PROs) are consid-
ered in the assessment of Class-III MDs in the US and EU. METHODS: The Drug
Approval Packages of MDs granted approval by the FDA from 2006-2011 were re-
viewed to identify MDs presenting PRO-related data. Ophthalmology MDs were
reviewed in greater detail to explore the range of PRO constructs presented. No
publically available database of EU MD approvals exists, making a parallel search
impossible. Instead, clinical trial databases (e.g. ClinicalTrials.gov) were searched
to identify EU-registered trials with PRO-endpoints for the ophthalmology MDs
identified from the US FDA review. RESULTS: The FDA approved 197 MDs from
2006-2011, of which 52(26.4%) presented PRO data. PRO-claims were lowest in 2008
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(15.5% approvals) and highest in 2006 (39.5%) but there was no clear trend over
time. Ophthalmology MDs (6 MDs with 7 approvals) primarily focused on symp-
toms, vision-related functioning and satisfaction. Only two used validated PRO-
instruments. In the EU, PRO endpoints were used in clinical trials for three of
the six ophthalmology MDs, and included symptoms, functioning and
health-related-quality-of-life. CONCLUSIONS: Discrepancies in the transparency
of the US/EU MD-approval process render comparative research impossible. How-
ever, PROs do not appear to be widely used in the assessment of MDs, particularly
in the EU. This is a missed opportunity to capture the patient-perspective on effi-
cacy and acceptability of MDs.
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Traditionally, the reporting of adverse drug reactions (ADRs) by health care profes-
sionals is recognized well. In the recent decades, the significance of consumer
reporting of ADRs have been give due attention in the developed nations. There are
documented reasons on the failure of health care professionals in reporting ADRs
communicated by the patients. OBJECTIVES: The present study aimed to evaluate
and compare the Pharmacovigilance systems in 70 different countries with regards
to consumer reporting of ADRs. METHODS: The official websites of regulatory/
medicines agencies or National Pharmacovigilance Centres of selected 70 coun-
tries, which joined the World Health Organization’s (WHO) International Drug
Monitoring Program between 1968 and 2010, were evaluated. RESULTS: In most of
the countries, health care professionals are legally obliged to report ADRs to the re-
spective medicines authorities. Only 17 countries (24.3%) accept ADR reports directly
from consumers. Of them, only 4 countries (5.7%) accept consumer reports by phone
and 11 countries (15.7%) have a web-based electronic system for consumer reporting.
CONCLUSIONS: The consumers report relatively untapped suspected reactions for
many prescription and non-prescription drugs. Recent literature from these countries
strongly stressed the WHO’s view in successful use of consumers as one of the valu-
able source of drug safety data. It is high time that the consumer reporting should be
encouraged in all the countries, especially the developing nations, for better drug
surveillance. Proper educational interventions are required to the general public to-
wards active involvement in the respective National Pharmacovigilance Programs,
which in turn improves the quality use of medicines.
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OBJECTIVES: Despite the increasing attention for active patient participation in
health care policy decisions, systematic use of the available evidence on collective
patient preferences (passive patient participation) is still limited. Objective of this
study is 1) explore opinions and ideas regarding the use of evidence on patient
preferences in coverage decisions and clinical practice guideline (CPG); 2) describe
how and what type of evidence on patient preferences is considered in health care
policy decisions in 5 European countries. METHODS: A literature search was per-
formed to identify opinion papers on patient preferences in the context of CPG or
coverage decisions. A document search was performed on websites and databases
of the responsible organisations of the Netherlands, England, Scotland, Germany
and France. Furthermore, a few coverage decisions and CPG were checked on the
subject. RESULTS: The debate on the integration of evidence on patient prefer-
ences concerns the definition and terminology of preferences, the question
whether patient or public values should be used for policy-making, the different
methods, quality and evidence synthesis of research on patient preferences, the
relevance of including patient preferences, and the discussion on outcomes be-
yond the QALY. The procedures for coverage decisions do not mention the search
for or use of evidence on patient preferences, nor was information found in the
coverage decisions. Only in the Scottish CPG procedure a literature search on pa-
tient evidence (not necessarily patient preferences) is obligatory prior to the first
meeting. In the Netherlands this is optional. Only the selected CPG from Nether-
lands, England and Scotland mention the use of information on patient prefer-
ences in different conceptualisations. CONCLUSIONS: In coverage decisions evi-
dence on patient preferences has no formal role yet. In CPG this role is limited.
Several issues and possible barriers are under debate regarding in the integration of
evidence on patient preferences in health care policy decision-making.
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FINANCIAL PENALTIES FOR IMPROVING DRUG ADHERENCE
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OBJECTIVES:Drug non-adherence is associated with significant negative economic
and public health burdens. The objective is to contribute to the literature on neg-
ative monetary incentives (i.e., penalties) by developing a discourse for an innova-
tive approach that could be validated in further experimental studies.METHODS:A
comprehensive database search (PubMed, EconLit) was conducted on economic
incentive programs to enhance adherence in drug therapy. Criteria for evaluation
of the retrieved economic studies have been taken from the literature. RESULTS:
Little evidence explicitly dealing with economic incentives in the form of monetary
sanctions in order to improve adherence or compliance was retrieved from the
literature search. Ethics legitimate incentive-based health care designs including
penalties if elements such as the standard of knowledge, social awareness, and
individual responsibility are well addressed and outweigh any profit orientation.
Transaction costs remain the main barrier in both institutional implementation
and practical enforcement of contractual monitoring and settlement of penalties.
Hence, a multifaceted approach would be necessary to present a sustainable con-
cept fulfilling the aspects of equal access to health care, social equity, and eco-
nomic viability. CONCLUSIONS: Financial penalties for drug non-adherence are
still a long way off as the concept lacks a simple solution. This paper contributes to
the widespread discussion by concentrating and aggregating widely scattered fig-
ures of dispute within a coherent argumentative discourse drawing on insights
from the field of health economics.
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OBJECTIVES: The first real independence makes student population exposed to
various health risks. The aim of this study was to examine the health of students
and their using of health care services and medicines. METHODS: The cross-sec-
tional study was carried out at the three State Universities from February to May in
the academic year 2011/2012. and included 2285 students of both sexes. The stu-
dents filled in a questionnaire consisting of 30 questions referring to socio-eco-
nomic characteristics, life-style habits, health assessment, as well as some health
problems and use of health services. RESULTS: Half of all students reported having
a selected physician. Of the total number of students 59.8% of them had been to the
doctor and 63.8% of students used the services of a dentist at least once in the year
preceding the survey. As the most common reasons for visiting general practitio-
ners, students cited the control of health and medical examinations (40.4%), the
existence of an illness or injury (32.1%), as well as instructions for obtaining a
specialist (11.7%). The average number of physician visit per student was 1.89 (SD
2.81) and the number of actual dental visit per student was 2.33 (SD 3.93). Of the
total number 77.2% of students had never been hospitalized. Most students taking
the medication on the advice of doctors (49.1%). Medication is not used at all for
24.2% of students. Cochran’s Q test showed a statistically significant difference
between groups of drugs which the students took on their own initiative, where the
first stand pain medication, and then the drugs to strengthen the body (p 0.001).
CONCLUSIONS: Universities should be encouraged to provide efficient, affordable
counseling services for their students. Students must be encouraged to become
actively involved in health promotion.
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OBJECTIVES: The use of antibiotics is found to be irrational by patients as well as
prescribers and lack of knowledge and information about the adverse effects and
the increasing prevalence of resistant organisms are some of the important factors
which caused it. So national education programs about the dangers of irrational
antibiotic use should be the priority. Affecting on these ideas in adults takes too
much time and money, but education is more effective in children and its effect on
a child becomes fixed in their beliefs. This study aimed to assess and compare the
effectiveness of wallpaper news and story book designed to teach children about
the benefits of appropriate use of antibiotics. METHODS: The children story book
and wallpaper news which have been designed and published by National Com-
mittee on Rational Use of Drug (NCRUD) were delivered to 18 primary school (9 for
girls and 9 for boys) that volunteered to participate in the study in Tehran. All
student of third, fourth and fifth grade have been educated by their trained teach-
ers. The evaluation of children’s Knowledge has been done on all of students before
and after intervention. RESULTS: The research results found that there was signif-
icant difference between the student knowledge before and after both interven-
tions in girls’ and boys’ primary schools. (p0.0001) and the effectiveness of wall
news paper is more than story book in girls’ primary school. (p0.006).
CONCLUSIONS: We conclude that children stories have good impression on the
level of student’s knowledge and it seems that teaching the students about the
advantages of appropriate antibiotic use by using children stories can influence
their knowledge significantly and its good way to increase their level of knowledge
and positive behavior in future life.
HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group
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HOW DO REIMBURSEMENT SYSTEMS ENCOURAGE OR INHIBIT ADOPTION OF
INNOVATIVE MEDICAL DEVICES IN AN AMBULATORY SETTING?
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OBJECTIVES:To consider how reimbursement systems in 5 EU countries encourage
or inhibit adoption of medical device technologies that facilitate care in an ambu-
latory setting. METHODS: A literature review of payment systems for medical de-
vices operating in England, Germany, Italy, France and Spain was undertaken.
Examples of technologies that could be used in an out-patient setting, but which
were predominantly being used in hospital were identified. Uterine balloon endo-
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